
|Videos|July 21, 2023
Impact of Personalized Dosing of Faricimab on Treatment Outcomes in nAMD
Author(s)Varun Chaudhary, MD, FRCS(C)
Dr Varun Chaudhary discusses the impact of personalized treat-and-extend-based dosing on visual and anatomic outcomes of faricimab in the TENAYA and LUCERNE clinical trials in neovascular AMD.
Advertisement
Episodes in this series
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Alvotech files first known aflibercept 8 mg biosimilar with EMA
3
FDA approves subcutaneous Enspryng for TED
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5


















